Investing.com - Bio-Rad Labs (NYSE: BIO) reported third quarter EPS of $2.01, $0.85 better than the analyst estimate of $1.16. Revenue for the quarter came in at $649.7M versus the consensus estimate of $628.18M.
Bio-Rad Labs's stock price closed at $330.58. It is down -1.59% in the last 3 months and up 20.09% in the last 12 months.
Bio-Rad Labs saw 0 positive EPS revisions and 4 negative EPS revisions in the last 90 days. See Bio-Rad Labs's stock price’s past reactions to earnings here.
According to InvestingPro, Bio-Rad Labs's Financial Health score is "good performance".
Check out Bio-Rad Labs's recent earnings performance, and Bio-Rad Labs's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar